This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Celldex (CLDX) Up 3.3% Since Last Earnings Report?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 21.43% and 2.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Celldex (CLDX) This Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is expected to be on the company's immuno-oncology pipeline in second-quarter earnings.
Celldex Therapeutics (CLDX) Down 9.2% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Celldex Therapeutics (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down
by Zacks Equity Research
Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.
Celldex (CLDX) Q1 Loss Narrower, Revenues Beat, Shares Down
by Indrajit Bandyopadhyay
Celldex (CLDX) beat earnings and sales estimates in the first quarter.
What's in Store for Celldex (CLDX) This Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on its immuno-oncology pipeline.
Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
by Zacks Equity Research
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
Celldex's Phase II Breast Cancer Study Fails, Shares Plunge
by Zacks Equity Research
Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.
Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock Options
by Zacks Equity Research
Surging implied volatility makes Celldex Therapeutics (CLDX) stock lucrative to the option traders.
Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss in Q4 with sales also beating estimates. Moreover, shares rise in after-hours trading on Mar 7 following the results.
AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.
What's in the Cards for Merck KGaA (MKGAF) in Q4 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments are likely to drive sales in Q4. However, the company's oncology drug fails in a phase III gastric cancer study.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Investors focus will be on pipeline and regulatory updates during Catalyst's (CPRX) fourth-quarter earnings call.
Is a Beat in the Cards for Celldex (CLDX) in Q4 Earnings?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on immuno-oncology pipeline.
AbbVie's Upadacitinib Gains Breakthrough Therapy Designation
by Zacks Equity Research
AbbVie's (ABBV) atopic dermatitis (eczema) candidate, upadacitinib, gets breakthrough therapy status from the FDA.
Amgen Announces Acceptance of MAA for Evenity in Europe
by Zacks Equity Research
Amgen's (AMGN) regulatory application seeking approval for Evenity as a treatment of osteoporosis gets EMA's acceptance.
4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio
by Zacks Equity Research
Celldex stock has been performing well for the last six months and the momentum is likely to continue in the near term.
TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise
by Zacks Equity Research
TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.
AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study
by Zacks Equity Research
AbbVie's (ABBV) RA candidate, upadacitinib, achieves statistically significant improvement in patients in phase III monotherapy study comparing it to methotrexate.
Minerva Initiates Phase III Study on Schizophrenia Candidate
by Zacks Equity Research
Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.
TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why
by Zacks Equity Research
TherapeuticsMD (TXMD) announces the acceptance of its resubmitted NDA for TX-004HR for treating dyspareunia as Class 2 response. A likely delay in approval drives shares down.
Shire's New Formulation of Oncaspar Gets Approval in Europe
by Zacks Equity Research
Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar receives approval from the European Commission.
Glaxo's Nucala Label Expansion Application Gets FDA Approval
by Zacks Equity Research
GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.